MOTS-c Enters Human Trials: What the First Phase 2a Study Will Actually Test

The Peptides Place Editorial Team

Oct 4

4 min read

Bottom line

MOTS-c — a mitochondrial-derived peptide with a large animal-research literature and zero human efficacy data — is now in its first interventional human trial. The Phase 2a study (NCT07505745, "MOTS-MET") is randomized, double-blind, and placebo-controlled: 120 adults with prediabetes and overweight or obesity receive either MOTS-c or placebo by daily subcutaneous injection for 12 weeks, with insulin sensitivity as the primary endpoint. The trial is currently recruiting, with primary completion estimated for February 2027.

This is a genuine milestone: the end of the "mice only" era for one of the most-searched longevity peptides. It is not, however, evidence that MOTS-c works in people. Registration is a promise to test, not a result.

What is MOTS-c?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded not in nuclear DNA but in mitochondrial DNA — unusual, and part of its mystique. In preclinical studies, it has been reported to regulate insulin sensitivity and metabolic homeostasis, with skeletal muscle identified as a key target tissue and AMPK activation proposed as a downstream mechanism. Mouse studies have shown effects on diet-induced obesity and age-related insulin resistance.

That is the entire human-relevant evidence base to date: animal and cell studies. Every claim about MOTS-c for longevity, metabolism, or "exercise in a syringe" currently rests on that foundation. The peptide also appeared in this year's regulatory news: it was one of six substances an FDA advisory committee recommended for the federal 503A compounding list in July — a recommendation about compounding eligibility, not a finding that it works (see our July 2026 PCAC vote explainer: https://www.thepeptidesplace.com/post/fda-peptide-compounding-update-what-the-july-2026-pcac-vote-actually-means).

What the trial will actually test

The details below are from the trial's ClinicalTrials.gov registration, posted April 1, 2026:

Design: Phase 2a, randomized 1:1, double-blind, placebo-controlled. Both arms also receive standardized lifestyle counseling.

Population: 120 adults, ages 18–65, BMI 27–40, with prediabetes (HbA1c 5.7–6.4%, or equivalent fasting/OGTT criteria). People with diabetes, or using glucose-lowering drugs including GLP-1s, are excluded.

Intervention: Fixed-dose MOTS-c by subcutaneous injection once daily for 12 weeks, then a 4-week safety follow-up.

Primary endpoints: Change in OGTT-derived insulin sensitivity (Matsuda Index) at 12 weeks, plus treatment-emergent adverse events through week 16.

Secondary endpoints: HbA1c, fasting glucose, 2-hour OGTT glucose, body weight, waist circumference, lipids, and immunogenicity (anti-drug antibodies).

Status: Recruiting. Study started February 2026; primary completion estimated February 2027; full completion estimated May 2028.

Sponsor and site: Hudson Biotech, a small biotech company, running at a single site — Peking University Shenzhen Hospital in Shenzhen, China.

What this trial can and can't prove

It can: Provide the first controlled human data on whether MOTS-c affects insulin sensitivity, and the first systematic human safety data. A clean positive on the Matsuda Index would be a real signal — the first ever in people.

It can't: Prove longevity benefits, establish an optimal dose for any consumer use, or say anything about healthy people, people with diabetes, or long-term effects. Twelve weeks in 120 people with prediabetes is an early efficacy-and-safety screen, not a validation of the peptide's internet reputation. And a single-site study by a small sponsor will need independent replication before the findings carry much weight — standard practice, not a special suspicion.

Why this matters now

Three reasons. First, MOTS-c is consistently among the most-searched "longevity peptides," which means the gap between public enthusiasm and human evidence has been enormous — this trial starts closing it. Second, it arrives alongside the FDA's compounding review, where MOTS-c's regulatory future is being decided in parallel with its scientific one; the two tracks shouldn't be confused. Third, it sets up a franchise worth following: trial registrations are news now, and results will be news later. We'll be watching for the readout.

What happens next

Recruitment is underway. The primary endpoint readout is estimated for early 2027, with the full study running into 2028. Between now and then, expect the gray market to keep selling MOTS-c with increasing boldness — none of it informed by this trial's data, which doesn't exist yet.

Frequently asked questions

Is MOTS-c approved for any use?

No. It is not approved by the FDA or any other regulator. Its only legitimate human use right now is inside this clinical trial.

Can I buy MOTS-c online?

You can find it for sale, but everything sold as MOTS-c today is unapproved and untested in humans — the trial testing it hasn't reported results. Our gray-market retatrutide investigation shows what that gamble has looked like for other peptides: https://www.thepeptidesplace.com/post/gray-market-retatrutide-injuries-tga-lab-tests

What does the Matsuda Index measure?

It's a validated estimate of whole-body insulin sensitivity derived from glucose and insulin measurements during a 75-gram oral glucose tolerance test. It's a well-established surrogate endpoint — meaningful, but not the same as showing fewer people develop diabetes.

When will we know if it works?

The trial's primary completion is estimated for February 2027. Results typically publish months after completion — and that's if the timeline holds, which it often doesn't.

The Peptides Place perspective

This is exactly the kind of development this site exists to track: a real trial, asking a real question, about a peptide drowning in premature claims. We'll follow MOTS-MET through completion and cover the readout when it lands — whatever it shows.

Sources

ClinicalTrials.gov: NCT07505745 — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (MOTS-MET): https://clinicaltrials.gov/study/NCT07505745

Trial background: mitochondrial-derived peptides and AMPK signaling (see Detailed Description in the registry entry above)

Regulatory notice

This article is for general educational purposes only and is not medical advice. Trial registration is not evidence of efficacy or safety. Nothing here is a recommendation to obtain, purchase, or use any peptide.